Phase 1 data presented on first oral combination 17β -estradiol and progesterone capsule to treat menopausal symptoms being developed for FDA review

TherapeuticsMD, Inc. (NYSE MKT:TXMD) - Pharmacokinetic study presented in a poster session at The North American Menopause Society 2013 Annual Meeting in Dallas suggests that the first combination 17β-estradiol and progesterone capsule in clinical development may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination. In a study of 66 healthy postmenopausal women, bioavailability of TX 12-001-HR, a capsule containing both 17β- estradiol and progesterone for oral use being developed by TherapeuticsMD, Inc...